Breaking Finance News

Zacks Investment Research issued a report on Palatin Technologies, Inc. (NYSE:PTN), upping its target price to $0.75 today

Palatin Technologies, Inc. (NYSE:PTN) had its price target upped to $0.75 by Zacks Investment Research in an issued report issued 09/23/2016. The upped price target implies a potential upside of 0.25% from the company's previous stock price.

Having a price of $0.60, Palatin Technologies, Inc. (NYSE:PTN) traded 9.09% higher on the day. With the last stock price up 14.97% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. PTN has recorded a 50-day average of $0.54 and a two hundred day average of $0.52. Trade Volume was up over the average, with 4,220,142 shares of PTN changing hands over the typical 970,503

Recent Performance Chart

Palatin Technologies, Inc. (NYSE:PTN)

Palatin Technologies, Inc. has with a one year low of $0.36 and a one year high of $0.90 and has a market capitalization of $0.

General Company Details For Palatin Technologies, Inc. (NYSE:PTN)

Palatin Technologies, Inc. is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. The Company's programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in clinical development is Bremelanotide, which is used for the treatment of female sexual dysfunction (FSD). In addition, the Company has drug candidates or development programs for obesity, erectile dysfunction, cardiovascular diseases, pulmonary diseases, inflammatory diseases and dermatologic diseases. Its other drug development programs include Melanocortin receptor-4 (MC4r); PL-3994, and Melanocortin receptor-1 (MC1r). It is developing other Melanocortin drug discovery programs in the melanocortin field, primarily developing peptide compounds, including MC1r agonists, and peptides specific for MC4r, including both agonists and antagonists.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.